SK279277B6 - Farmaceutický prostriedok proti aterosklerotickému - Google Patents

Farmaceutický prostriedok proti aterosklerotickému Download PDF

Info

Publication number
SK279277B6
SK279277B6 SK3027-92A SK302792A SK279277B6 SK 279277 B6 SK279277 B6 SK 279277B6 SK 302792 A SK302792 A SK 302792A SK 279277 B6 SK279277 B6 SK 279277B6
Authority
SK
Slovakia
Prior art keywords
pharmaceutical composition
compound
composition according
active ingredient
formula
Prior art date
Application number
SK3027-92A
Other languages
English (en)
Slovak (sk)
Other versions
SK302792A3 (en
Inventor
Yasushi Saito
Masaki Kitahara
Mitsuaki Sakashita
Kyomi Toyoda
Tashie Shibazaki
Original Assignee
Nissan Chemical Industries Ltd.
Kowa Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nissan Chemical Industries Ltd., Kowa Company filed Critical Nissan Chemical Industries Ltd.
Publication of SK302792A3 publication Critical patent/SK302792A3/sk
Publication of SK279277B6 publication Critical patent/SK279277B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SK3027-92A 1991-10-04 1992-10-02 Farmaceutický prostriedok proti aterosklerotickému SK279277B6 (sk)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP03257870A JP3130342B2 (ja) 1991-10-04 1991-10-04 動脈硬化性血管内膜肥厚抑制薬

Publications (2)

Publication Number Publication Date
SK302792A3 SK302792A3 (en) 1995-11-08
SK279277B6 true SK279277B6 (sk) 1998-09-09

Family

ID=17312323

Family Applications (1)

Application Number Title Priority Date Filing Date
SK3027-92A SK279277B6 (sk) 1991-10-04 1992-10-02 Farmaceutický prostriedok proti aterosklerotickému

Country Status (18)

Country Link
US (1) US6162798A (no)
EP (1) EP0535548B1 (no)
JP (1) JP3130342B2 (no)
KR (1) KR100264543B1 (no)
AT (1) ATE209035T1 (no)
AU (1) AU652669B2 (no)
CA (1) CA2079706C (no)
CZ (1) CZ281786B6 (no)
DE (1) DE69232217T2 (no)
DK (1) DK0535548T3 (no)
HU (1) HU214624B (no)
MX (1) MX9205659A (no)
NO (1) NO302452B1 (no)
NZ (1) NZ244555A (no)
RU (1) RU2114620C1 (no)
SK (1) SK279277B6 (no)
TW (1) TW238300B (no)
UA (1) UA39095C2 (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011898A1 (en) * 1992-05-12 1995-05-04 Nissan Chemical Industries Ltd. Condensed pyridine type mevalonolactone intermediate and process for its production
RU2145852C1 (ru) * 1996-01-17 2000-02-27 Тайхо Фармасьютикал Ко., Лтд Ингибитор гипертрофии интимы, применение оксиндолового производного для получения ингибитора гипертрофии интимы, композиция для ингибирования гипертрофии интимы, способ предупреждения и лечения гипертрофии интимы
PT1099694E (pt) * 1998-07-23 2005-10-31 Nissan Chemical Ind Ltd Processo para a preparacao de um derivado de quinolina e um intermediario para esse fim
JP4714992B2 (ja) 1999-01-14 2011-07-06 日産化学工業株式会社 キノリンカルボアルデヒドの製造法
JP4496584B2 (ja) * 2000-01-24 2010-07-07 日産化学工業株式会社 キノリルプロペナールの製造法
CN1222512C (zh) * 2000-01-24 2005-10-12 日产化学工业株式会社 喹啉基丙烯醛的制备方法
JP4496585B2 (ja) * 2000-01-24 2010-07-07 日産化学工業株式会社 キノリルプロペナールの製造方法
JP4496586B2 (ja) * 2000-01-24 2010-07-07 日産化学工業株式会社 キノリルアクリロニトリルの製造法及びその中間体
JP4867071B2 (ja) * 2000-02-21 2012-02-01 日産化学工業株式会社 キノリン誘導体の製造方法
US6855824B2 (en) 2000-02-21 2005-02-15 Kuraray Co., Ltd. Processes for preparing quinoline derivatives and intermediates thereof
AU2001264313A1 (en) * 2000-06-20 2002-01-02 Japan Tobacco Inc. Pyrazolopyridine compounds and use thereof as drugs
JP2005525368A (ja) * 2002-03-04 2005-08-25 メディミューン，インコーポレーテッド インテグリンαｖβ３アンタゴニストをＨＭＧ−ＣｏＡ還元酵素阻害剤またはビスフォスフォネートと併用投与する障害の予防または治療方法
CN100378077C (zh) * 2002-11-06 2008-04-02 日产化学工业株式会社 喹啉甲醛类的制造方法
EP1568693A4 (en) * 2002-11-06 2007-09-05 Nissan Chemical Ind Ltd PROCESS FOR PRODUCING QUINOLINECARBALDEHYDE
US7420059B2 (en) * 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
BRPI0417543A (pt) 2003-12-12 2007-03-27 Wyeth Corp quinolinas úteis no tratamento de doença cardiovascular
US7459451B2 (en) * 2004-07-05 2008-12-02 Astellas Pharma Inc. Pyrazolopyridine derivatives
CN100445267C (zh) * 2005-10-21 2008-12-24 上海医药工业研究院 4-(4-氟-苯基)-3-羟甲基-2-环丙基-喹啉的制备方法
JP6189948B2 (ja) 2012-06-29 2017-08-30 ファイザー・インク ＬＲＲＫ２阻害薬としての新規な４−（置換アミノ）−７Ｈ−ピロロ［２，３−ｄ］ピリミジン
CN103204807B (zh) * 2013-04-08 2015-12-23 黄河三角洲京博化工研究院有限公司 一种2-环丙基-4-（4-氟-苯基）-3-喹啉甲醛的合成方法
TWI634120B (zh) * 2013-12-13 2018-09-01 日商第一三共股份有限公司 ５－羥基－４－（三氟甲基）吡唑并吡啶衍生物及其用途
US9695171B2 (en) 2013-12-17 2017-07-04 Pfizer Inc. 3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors
CN104031034B (zh) * 2014-07-01 2017-01-04 上海信谊百路达药业有限公司 一种匹伐他汀钙原料药中间体的制备方法
RU2722149C1 (ru) 2015-09-14 2020-05-27 Пфайзер Инк. Новые производные имидазо[4,5-c] хинолинов и имидазо[4,5-c][1,5] нафтиридинов в качестве ингибиторов LRRK2

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1336714C (en) * 1987-08-20 1995-08-15 Yoshihiro Fujikawa Quinoline type mevalonolactone inhibitors of cholesterol biosynthesis
JP2569746B2 (ja) * 1987-08-20 1997-01-08 日産化学工業株式会社 キノリン系メバロノラクトン類
US4761419A (en) * 1987-12-07 1988-08-02 Warner-Lambert Company 6-(((substituted)quinolinyl)ethyl)-and ethenyl)tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
US4822799A (en) * 1988-01-27 1989-04-18 Sandoz Pharm. Corp. Pyrazolopyridine analogs of mevalonolactone and derivatives thereof useful for inhibiting cholesterol biosynthesis in mammals
JP2890448B2 (ja) * 1988-04-26 1999-05-17 日産化学工業株式会社 ピラゾロピリジン系メバロノラクトン類
US5024999A (en) * 1988-04-26 1991-06-18 Nissan Chemical Industries Ltd. Pyrazolopyridine type mevalonolactones useful as pharmaeuticals
US5026698A (en) * 1988-11-02 1991-06-25 Nissan Chemical Industries, Ltd. Thienopyridine type mevalonolactones

Also Published As

Publication number Publication date
EP0535548B1 (en) 2001-11-21
AU2601292A (en) 1993-04-08
RU2114620C1 (ru) 1998-07-10
MX9205659A (es) 1993-04-01
JP3130342B2 (ja) 2001-01-31
DK0535548T3 (da) 2002-05-13
SK302792A3 (en) 1995-11-08
NO302452B1 (no) 1998-03-09
EP0535548A1 (en) 1993-04-07
KR100264543B1 (ko) 2001-10-24
KR930007449A (ko) 1993-05-20
CZ302792A3 (en) 1993-10-13
DE69232217T2 (de) 2002-05-23
CZ281786B6 (cs) 1997-01-15
DE69232217D1 (de) 2002-01-03
ATE209035T1 (de) 2001-12-15
HU214624B (hu) 1998-04-28
NO923858L (no) 1993-04-05
AU652669B2 (en) 1994-09-01
TW238300B (no) 1995-01-11
NO923858D0 (no) 1992-10-02
CA2079706A1 (en) 1993-04-15
US6162798A (en) 2000-12-19
HUT62794A (en) 1993-06-28
JPH06329540A (ja) 1994-11-29
NZ244555A (en) 2000-06-23
CA2079706C (en) 2004-03-30
UA39095C2 (uk) 2001-06-15

Similar Documents

Publication Publication Date Title
SK279277B6 (sk) Farmaceutický prostriedok proti aterosklerotickému
ES2547153T3 (es) Derivados de 8-alcoxi-aminotetralina sustituidos y su uso
US7105532B2 (en) Pyrazolo[3,4-c]pyridines as gsk-3 inhibitors
JP6324956B2 (ja) 置換アミノインダン−およびアミノテトラリンカルボン酸ならびにその使用
CA3111725C (en) 2,6-diamino pyridine compounds
EA026300B1 (ru) Активаторы ampk и их применение в терапевтических целях
DE10057751A1 (de) Neue Carbamat-substituierte Pyrazolopyridinderivate
WO2012012712A2 (en) Tricyclic proteasome activity enhancing compounds
US20060194827A1 (en) 5-Cycloalkenyl 5H-chromeno[3,4-f]quinoline derivatives as selective progesterone receptor modulator compounds
KR100300566B1 (ko) 피리미디논유도체와그의제조방법및용도
JPH05140162A (ja) 精神的疾病を治療するための製薬学的調剤、ピリダジンジオン化合物および該化合物の製造法
FR2593818A1 (fr) Derives d'acylaminomethyl-3 imidazo(1,2-a)pyridine, leur preparation et leur application en therapeutique
JP7329509B2 (ja) 中枢および末梢神経系障害の治療のためのキナーゼ阻害剤
WO2016206576A1 (zh) 一种氘代噻吩并哌啶衍生物、制备方法及其应用
RU2666727C1 (ru) Ингибитор вируса гепатита В (ВГВ)
US5010084A (en) Imidazoquinolone derivatives
JP4354016B2 (ja) 新規プリン誘導体およびこれを含む医薬組成物
JP2009051731A (ja) 新規アスコクロリン誘導体化合物及びそれを含有する医薬組成物
EP0293146A1 (en) Benzofuro [3,2-c] quinoline compounds
CZ280922B6 (cs) Kyseliny alfa-oxopyrrolo/2,3-b/indoloctové a jejich estery, amidy a analogy, způsob jejich přípravy a jejich použití jako léčiva
JPH0395166A (ja) イソキサゾロン誘導体含有脳機能改善剤
KR19990007796A (ko) 혈관 신생 억제제
US20060173069A1 (en) Therapeutic agent for hyperpotassemia and bone disease
KR100501843B1 (ko) 새로운 항암성 비타민 ｄ₃유도체
US5308851A (en) Bispyridyl-containing heterocycles useful for treating cognitive disorders

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20101002